IFN-λ uniquely promotes CD8 T cell immunity against SARS-CoV-2 relative to type I IFN
- PMID: 38973611
- PMCID: PMC11383353
- DOI: 10.1172/jci.insight.171830
IFN-λ uniquely promotes CD8 T cell immunity against SARS-CoV-2 relative to type I IFN
Abstract
Optimization of protective immune responses against SARS-CoV-2 remains an urgent worldwide priority. In this regard, type III IFN (IFN-λ) restricts SARS-CoV-2 infection in vitro, and treatment with IFN-λ limits infection, inflammation, and pathogenesis in murine models. Furthermore, IFN-λ has been developed for clinical use to limit COVID-19 severity. However, whether endogenous IFN-λ signaling has an effect on SARS-CoV-2 antiviral immunity and long-term immune protection in vivo is unknown. In this study, we identified a requirement for IFN-λ signaling in promoting viral clearance and protective immune programming in SARS-CoV-2 infection of mice. Expression of both IFN and IFN-stimulated gene (ISG) in the lungs were minimally affected by the absence of IFN-λ signaling and correlated with transient increases in viral titers. We found that IFN-λ supported the generation of protective CD8 T cell responses against SARS-CoV-2 by facilitating accumulation of CD103+ DC in lung draining lymph nodes (dLN). IFN-λ signaling specifically in DCs promoted the upregulation of costimulatory molecules and the proliferation of CD8 T cells. Intriguingly, antigen-specific CD8 T cell immunity to SARS-CoV-2 was independent of type I IFN signaling, revealing a nonredundant function of IFN-λ. Overall, these studies demonstrate a critical role for IFN-λ in protective innate and adaptive immunity upon infection with SARS-CoV-2 and suggest that IFN-λ serves as an immune adjuvant to support CD8 T cell immunity.
Keywords: Immunology; Infectious disease; Innate immunity; Mouse models; T cells.
Conflict of interest statement
Figures
References
MeSH terms
Substances
Grants and funding
- 75N92020D00005/HL/NHLBI NIH HHS/United States
- 75N93022D00005/AI/NIAID NIH HHS/United States
- R01 HL168501/HL/NHLBI NIH HHS/United States
- R21 AI151230/AI/NIAID NIH HHS/United States
- 75N93023D00005/AI/NIAID NIH HHS/United States
- R35 GM150503/GM/NIGMS NIH HHS/United States
- R35 GM150806/GM/NIGMS NIH HHS/United States
- R21 AI174050/AI/NIAID NIH HHS/United States
- 75N95020D00005/DA/NIDA NIH HHS/United States
- R01 HL154001/HL/NHLBI NIH HHS/United States
- K22 AI146141/AI/NIAID NIH HHS/United States
- 75N99020D00005/OF/ORFDO NIH HHS/United States
- T32 AI165391/AI/NIAID NIH HHS/United States
- R01 AI130110/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous
